Alzheimer’s Disease Diagnosis Time Outs: A Deep Dive into Challenging Clinical Scenarios for Early Alzheimer's Diagnosis and Treatment

Program Description

The management of AD is at the beginning of a seismic paradigm shift. Historically, clinical strategy has been tailored to a therapeutic armamentarium that was nonspecific and directed solely at symptom management. This mindset coincides with a variety of outdated and potentially harmful assumptions such as the idea that early diagnosis provides limited clinical value. Now that anti-Aβ antibodies are making their way into the clinic, the entire spectrum of AD care, from diagnosis through therapy, must be re-engineered.

The Clinical Toolkit is available for download here. 

Target Audience

This activity is intended for neurologists, geriatricians, geriatric psychiatrists, radiologists, neuroradiologists, neurodegenerative disease specialists, nurse practitioners, physician associates, and other healthcare professionals involved in the care of patients with early AD.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • Apply current recommendations/best practices for the identification and counseling of individuals eligible for new anti-Aβ antibodies
  • Evaluate the efficacy, safety, and administration/monitoring requirements of approved anti-Aβ antibodies to optimize treatment selection and long-term use for eligible patients
  • Implement optimal strategies for identification and management of ARIA and appraise current views on the risks of antithrombotics for patients on anti-Aβ antibodies
Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance
Course opens: 
02/14/2025
Course expires: 
02/14/2026
Cost:
$0.00
Rating: 
0

   James E. Galvin, MD, MPH, FANA (Chair)
   Director, Comprehensive Program for Brain Health
   Professor, Department of Neurology
   University of Miami Miller School of Medicine
   Miami, FL

 

 

   George T Grossberg MD
   Inaugural Henry & Amelia Nasrallah Endowed Professor
   Director, Division of Geriatric Psychiatry
   Department of Psychiatry & Behavioral Neuroscience
   St Louis University School of Medicine
   St Louis, MO

 
   B. Joy Snider, MD, PhD
   Professor of Neurology
   Knight Alzheimer Disease Research Center
   Washington University School of Medicine
   Saint Louis, MO

This activity is jointly provided by Medical Education Resources (MER) and Efficient LLC.

image               image     

Joint Accreditation Statement

image

In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and Efficient LLC. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

PHYSICIAN CREDIT
Medical Education Resources designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
 
PHYSICIAN ASSOCIATES CREDIT 
Medical Education Resources has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.00 AAPA Category 1 CME Credit. Physician Associates should only claim credit commensurate with the extent of their participation.
 
CERTIFICATE OF PARTICIPATION FOR OTHER HEALTHCARE PROFESSIONALS
A Certificate of Participation will be given upon completion of the enduring activity enabling participants to register their credit with the appropriate licensing boards or associations.

Staff Disclosures

Efficient LLC and Medical Education Resources' planners and managers have no financial relationships to disclose.

Faculty Disclosures

James E. Galvin, MD, MPH, FANA reported the following relationships:

  • Consulting Fees: Alpha Cognition; Biogen; Cognivue; Eisai; Eli Lilly; Genentech/Roche; Otsuka

George T Grossberg MD reported the following relationships:

  • Consulting Fees: Acadia; Avanir; Axsome Therapeutics; Biogen; BioXcel; Eisai; Genentech; Karuna; Eli Lilly; Lundbeck; Maplight Therapeutics; Otsuka; Roche; Takeda
  • Research Support: NIA, Functional Neuromodulation
  • Safety Monitoring Committee: Anavex; EryDel; Intra-Cellular Therapies; Merck; Newron; Oligomerix
  • Speakers Bureau: Biogen; Eisai

B. Joy Snider, MD, PhD reported the following relationships:

  • Grants/Research: Biogen; Eisai; JNJ; Roche (serve as site PI for clinical trials)
  • Consulting Fees: Eisai; Roche

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, Efficient LLC, and/or Eisai and Lilly. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

Commercial Support

This activity is supported by educational grants from Eisai and Eli-Lilly.

Method of Participation

There are no fees for participating in and receiving credit for this activity. During the period February 14, 2025, through February 14, 2026, participants must: 1) review the learning objectives and faculty disclosures; 2)complete the pre-activity assessment; 3) watch the educational activity;4) complete the posttest by recording the best answer to each question; and 5) complete the evaluation form.

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

Media

Internet

Available Credit

  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Attendance

Price

Cost:
$0.00
Please login or register to take this course.